Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions
Alpha-1 Antitrypsin DeficiencyAATD
Interventions
DRUG

INBRX-101/rhAAT-Fc

INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).

Trial Locations (10)

32611

University of Florida College of Medicine, Gainesville

33125

University of Miami, Miami

46202

Indiana University, Indianapolis

63401

Hannibal Clinic, Hannibal

95817

UC Davis School of Medicine, Sacramento

Unknown

The New Zealand Respiratory and Sleep Institute, Auckland

Christchurch Clinical Studies Trust Ltd, Christchurch

Waikato Respiratory and Gastro Research Unit, Hamilton

CB2 0QQ

University of Cambridge, Cambridge

B15 2GW

University Hospital Birmingham NHS Foundation Trust, Birmingham

Sponsors
All Listed Sponsors
lead

Inhibrx Biosciences, Inc

INDUSTRY

NCT03815396 - Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency | Biotech Hunter | Biotech Hunter